A novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development, and the genetics of NAFLD
Posted 27th March 2019 by Joshua Sewell
Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available.
|Alexandre Grassin talks about GKT831, a NOX1 and NOX4 inhibitor. GKT831 is evaluated in phase 2 clinical trials in primary
biliary cholangitis (PBC) and in an investigator-initiated Phase 2
clinical trial in Type 1 Diabetes and Kidney Disease (DKD).
|Hepatic fat accumulation and nonalcoholic fatty liver disease (NAFLD), especially the progressive form of the disease, have a strong heritable component. Luca Valenti discusses I148M variant of PNPLA3 is the main common genetic determinant of NAFLD.|
Want to read more on NASH and NAFLD? Good news! Our resources page is packed full of slides and presentation videos, why not take a look now?
Leave a Reply